Patients with very high-risk ASCVD (e.g., multiple major ASCVD events or one major ASCVD event plus multiple risk factors) who cannot reach an LDL threshold of 70 mg/dL (1.8 mmol/L) with a statin: ezetimibe add-on is reasonable. Failing that, a PCSK9 inhibitor* could be added.
Adding ezetimibe to simvastatin 40 mg post-ACS prevents one CV event for every 50 patients treated for seven years vs simvastatin alone.5 Added to a high- or moderate-intensity statin, evolocumab prevents one CV death, MI, or stroke for every 67 high-risk ASCVD patients treated for about two years (FOURIER study). CV death as a stand-alone outcome not affected. Most patients had a prior MI, and about one third had diabetes and/or smoked.4 Patients 20 to 75 years of age with LDL ≥190 mg/dL (4.9 mmol/L) who cannot achieve a 50% LDL reduction and/or LDL <100 mg/dL (2.6 mmol/L) with a statin: ezetimibe add-on is reasonable. If LDL threshold still not met and fasting triglycerides ≤300 mg/dL (3.4 mmol/L), add-on bile acid sequestrant can be considered. Failing this, if the patient has multiple risk factors, consider a PCSK9 inhibitor.*
Patients 30 to 75 years of age with heterozygous familial hypercholesterolemia with an LDL ≥100 mg/dL (2.6 mmol/L) despite statin and ezetimibe, consider adding a PCSK9 inhibitor.*
Patients 40 to 75 years of age with LDL ≥220 mg/dL (5.7 mmol/L) who cannot achieve an LDL <130 mg/dL (3.4 mmol/L) with a statin plus ezetimibe, consider adding a PCSK9 inhibitor.*
Primary prevention in adults 40 to 75 years of age with LDL 70 to 189 mg/dL (1.8 to 4.9 mmol/L) and an estimated 10-year risk of ASCVD of 7.5% or higher and CKD, can combine ezetimibe with a moderate-intensity statin.
Primary prevention in adults with diabetes and 10-year ASCVD risk ≥20%, it may be reasonable to add ezetimibe to a statin to achieve a ≥50% LDL reduction.
Triglycerides ≥500 mg/dL (5.7 mmol/L) and especially ≥1,000 mg/dL (11.3 mmol/L) despite lifestyle changes (very low-fat diet with increased omega-3 consumption, cutting refined carbohydrates and alcohol) and ruling out secondary causes: fibrate. Do not add gemfibrozil to statin.
As a statin substitute in patients with severe or recurrent statin muscle symptoms despite appropriate rechallenge.
Keep in mind that there is no proof adding a non-statin to a statin prevents events in patients without clinical ASCVD.
*PCSK9 inhibitor: safety past three years is unclear and cost is high. Benefit for event reduction is uncertain in patients without clinical ASCVD.
Risk-enhancing factors: metabolic syndrome, LDL persistently ≥160 mg/dL (≥4.1 mmol/L), CKD (see below), history of preeclampsia, family history of premature ASCVD, menopause at <40 years of age, chronic inflammatory disease (e.g., rheumatoid arthritis, HIV), ethnicity (e.g., South Asian), triglycerides persistently ≥175 mg/dL. In some patients (e.g., with estimated 10-year risk ASCVD risk <20%), elevated apolipoprotein B and/or lipoprotein (a), high-sensitivity C-reactive protein ≥2 mg/L, or ABI <0.9, may better-inform the risk/benefit discussion regarding statin therapy. In patients with triglyceride ≥200 mg/dL, apolipoprotein B ≥130 mg/dL corresponds to an LDL ≥160 mg/dL, and thus is a risk-enhancing factor. Persistent apolipoprotein B elevation can also be considered a risk-enhancing factor. Note that measurement may be inaccurate in some labs. Consider checking lipoprotein (a), a particularly atherogenic form of LDL, in patients with a family history of premature ASCVD. Levels ≥50 mg/dL (≥125 nmol/L) may be considered a risk-enhancing factor in men, especially at higher levels. In women, its ability to improve risk prediction is minimal, and only in women with hypercholesterolemia. CKD: use a moderate-intensity statin ±ezetimibe. Do not start a statin in dialysis patients, but it is reasonable to continue one if they are already taking it.
For how we tailor cholesterol care to each patient, see our Cholesterol Treatment Irving page. Questions about what your plan covers? Our Insurance page walks through it.
